News
XTNT
0.3200
-28.25%
-0.1260
Xtant Medical misses top-line and bottom-line estimates; lowers FY2026 outlook
Seeking Alpha · 17h ago
*Xtant Medical Holdings Cuts 2026 View To Rev $99M-$103M >XTNT
Dow Jones · 18h ago
Xtant Medical lowers 2026 revenue view to $99M-$103M from $101M-$105M
TipRanks · 18h ago
Xtant Medical Hldgs Lowers FY2026 Sales Guidance from $101.000M-$105.000M to $99.000M-$103.000M vs $102.058M Est
Benzinga · 18h ago
Press Release: Xtant Medical Reports Second -2-
Dow Jones · 18h ago
*Xtant Medical Holdings 2Q Loss $9.41M >XTNT
Dow Jones · 18h ago
*Xtant Medical Holdings 2Q Rev $23M >XTNT
Dow Jones · 18h ago
Press Release: Xtant Medical Reports Second Quarter 2026 Financial Results
Dow Jones · 18h ago
Weekly Report: what happened at XTNT last week (0803-0807)?
Weekly Report · 1d ago
Xtant Medical Stockholders Approve Governance and Leadership Items
TipRanks · 4d ago
Xtant Medical to Announce Second Quarter 2026 Financial Results on August 11, 2026
PR Newswire · 5d ago
Xtant Medical to Participate in the Canaccord Genuity 46th Annual Growth Conference
PR Newswire · 08/04 20:05
Weekly Report: what happened at XTNT last week (0727-0731)?
Weekly Report · 08/03 09:46
Weekly Report: what happened at XTNT last week (0720-0724)?
Weekly Report · 07/27 09:49
Weekly Report: what happened at XTNT last week (0713-0717)?
Weekly Report · 07/20 09:47
Weekly Report: what happened at XTNT last week (0706-0710)?
Weekly Report · 07/13 09:48
Weekly Report: what happened at XTNT last week (0629-0703)?
Weekly Report · 07/06 09:50
Weekly Report: what happened at XTNT last week (0622-0626)?
Weekly Report · 06/29 09:47
Weekly Report: what happened at XTNT last week (0615-0619)?
Weekly Report · 06/22 09:53
Weekly Report: what happened at XTNT last week (0608-0612)?
Weekly Report · 06/15 09:54
More
Webull provides a variety of real-time XTNT stock news. You can receive the latest news about Xtant Medical through multiple platforms. This information may help you make smarter investment decisions.
About XTNT
Xtant Medical Holdings, Inc. is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. The Company's products serve the specialized needs of orthopedic and neurological surgeons, as well as trauma, foot and ankle, sports medicine, wound care surgeons including orthobiologics for the promotion of bone healing, amniotic tissue and collagen for both surgical repair and chronic wound care, implants and instrumentation for the treatment of spinal disease. Its orthobiologics products include OsteoSponge, OsteoSelect DBM Putty, OsteoSelect PLUS DBM Putty, 3Demin, OsteoFactor Pro, OsteoVive Plus, and nanOss. Its spinal implant product categories include cervical, thoracolumbar, sacroiliac joint, and interbody. The Company has exclusive United States distribution rights to Dilon's HEMOBLAST Bellows.